FAM120B

Summary

FAM120B (family with sequence similarity 120 member B, HGNC:21109) is a protein-coding gene on chromosome 6q27, encoding Constitutive coactivator of peroxisome proliferator-activated receptor gamma (Q96EK7). Functions as a transactivator of PPARG and ESR1.

Predicted to be involved in fat cell differentiation and peroxisome proliferator activated receptor signaling pathway. Predicted to be active in nucleus.

Source: NCBI Gene 84498 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 135 total
• MANE Select transcript: NM_032448

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21109
Approved symbol	FAM120B
Name	family with sequence similarity 120 member B
Location	6q27
Locus type	gene with protein product
Status	Approved
Aliases	PGCC1, CCPG, SAN1
Ensembl gene	ENSG00000112584
Ensembl biotype	protein_coding
OMIM	612266
Entrez	84498

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 25 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000476287, ENST00000496635, ENST00000537664, ENST00000625626, ENST00000630384, ENST00000901517, ENST00000901518, ENST00000901519, ENST00000901520, ENST00000901521, ENST00000901522, ENST00000915624, ENST00000915625, ENST00000915626, ENST00000915627, ENST00000915628, ENST00000966364, ENST00000966365, ENST00000966366, ENST00000966367, ENST00000966368, ENST00000966369, ENST00000966370, ENST00000966371, ENST00000966372, ENST00000966373

RefSeq mRNA: 4 — MANE Select: NM_032448 NM_001286379, NM_001286380, NM_001286381, NM_032448

CCDS: CCDS5314, CCDS69243, CCDS75555, CCDS78200

Canonical transcript exons

ENST00000476287 — 11 exons

Exon	Start	End
ENSE00001149875	170391013	170391121
ENSE00001282246	170395487	170395579
ENSE00001900474	170404763	170407067
ENSE00002146799	170323079	170323259
ENSE00002178626	170358226	170358318
ENSE00002180535	170388287	170388493
ENSE00002184114	170348151	170348323
ENSE00003468202	170317370	170319124
ENSE00003474409	170404550	170404601
ENSE00003579893	170330449	170330550
ENSE00003774628	170306758	170306842

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 90.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 31.7616 / max 258.3651, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
71294	30.4165	1813
71295	1.3451	778

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	90.40	gold quality
right testis	UBERON:0004534	89.33	gold quality
left testis	UBERON:0004533	89.18	gold quality
prostate gland	UBERON:0002367	88.78	gold quality
testis	UBERON:0000473	88.54	gold quality
primary visual cortex	UBERON:0002436	88.36	gold quality
tibial nerve	UBERON:0001323	88.22	gold quality
endocervix	UBERON:0000458	88.08	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.03	gold quality
hypothalamus	UBERON:0001898	87.97	gold quality
fallopian tube	UBERON:0003889	87.97	gold quality
pituitary gland	UBERON:0000007	87.95	gold quality
lower esophagus mucosa	UBERON:0035834	87.94	gold quality
minor salivary gland	UBERON:0001830	87.91	gold quality
adenohypophysis	UBERON:0002196	87.88	gold quality
saliva-secreting gland	UBERON:0001044	87.87	gold quality
islet of Langerhans	UBERON:0000006	87.81	gold quality
endometrium	UBERON:0001295	87.78	gold quality
cerebellar hemisphere	UBERON:0002245	87.74	gold quality
cerebellum	UBERON:0002037	87.72	gold quality
cerebellar cortex	UBERON:0002129	87.72	gold quality
corpus callosum	UBERON:0002336	87.69	gold quality
Brodmann (1909) area 9	UBERON:0013540	87.63	gold quality
stromal cell of endometrium	CL:0002255	87.56	gold quality
uterine cervix	UBERON:0000002	87.56	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	87.54	gold quality
myometrium	UBERON:0001296	87.50	gold quality
nucleus accumbens	UBERON:0001882	87.49	gold quality
mucosa of transverse colon	UBERON:0004991	87.47	gold quality
left ovary	UBERON:0002119	87.45	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.25

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting FAM120B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-1208	99.70	68.28	1533

Literature-anchored findings (GeneRIF, showing 2)

• Study report a previously uncharacterized protein, SAN1, the Fam120b gene product, as a 5’ exonuclease that acts independently of the Fanconi anemia pathway in response to inter-strand DNA cross-links (ICLs). Deletion of SAN1 in HeLa cells and mouse embryonic fibroblasts causes sensitivity to ICLs. SAN1 binds to senataxin (SETX). SAN1-SETX binding is increased by ICLs and is required to prevent cross-link sensitivity. (PMID:29968717)
• San1 deficiency leads to cardiomyopathy due to excessive R-loop-associated DNA damage and cardiomyocyte hypoplasia. (PMID:34339838)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam120b	ENSDARG00000030804
mus_musculus	Fam120b	ENSMUSG00000014763
rattus_norvegicus	Fam120b	ENSRNOG00000058790

Paralogs (2): FAM120A (ENSG00000048828), FAM120C (ENSG00000184083)

Protein

Protein identifiers

Constitutive coactivator of peroxisome proliferator-activated receptor gamma — Q96EK7 (reviewed: Q96EK7)

Alternative names: PPARG constitutive coactivator 1, Protein FAM120B

All UniProt accessions (3): A0A0D9SEJ5, Q96EK7, F5GY05

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a transactivator of PPARG and ESR1. Functions in adipogenesis through PPARG activation.

Subunit / interactions. Interacts with ESR1 and RXRA. Interacts with PPARG; in a ligand-independent manner.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed.

Similarity. Belongs to the constitutive coactivator of PPAR-gamma family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96EK7-1	1	yes
Q96EK7-2	2
Q96EK7-3	3

RefSeq proteins (4): NP_001273308, NP_001273309, NP_001273310, NP_115824* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026784	Coact_PPARg	Family
IPR029060	PIN-like_dom_sf	Homologous_superfamily

UniProt features (21 total): sequence variant 8, compositionally biased region 5, region of interest 3, splice variant 3, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96EK7-F1	71.92	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 885

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation

MSigDB gene sets: 109 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, CAGCTG_AP4_Q5, GOBP_FAT_CELL_DIFFERENTIATION, GOBP_INTRACELLULAR_RECEPTOR_SIGNALING_PATHWAY, chr6q27, PID_RXR_VDR_PATHWAY, KOYAMA_SEMA3B_TARGETS_DN, GOBP_PEROXISOME_PROLIFERATOR_ACTIVATED_RECEPTOR_SIGNALING_PATHWAY, REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA, REACTOME_METABOLISM_OF_LIPIDS, GSE14415_ACT_VS_CTRL_NATURAL_TREG_DN, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_UP, GSE14415_INDUCED_VS_NATURAL_TREG_UP, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_DN, GSE13547_WT_VS_ZFX_KO_BCELL_ANTI_IGM_STIM_2H_DN

GO Biological Process (3): peroxisome proliferator activated receptor signaling pathway (GO:0035357), fat cell differentiation (GO:0045444), cell differentiation (GO:0030154)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Adipogenesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear receptor-mediated signaling pathway	1
cell differentiation	1
cellular developmental process	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1232 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM120B	UBR1	Q8IWV7	720
FAM120B	A0A090J7P6	A0A090J7P6	719
FAM120B	ERCC5	P28715	673
FAM120B	MARCHF6	O60337	642
FAM120B	PPARG	P37231	639
FAM120B	PSMB1	P20618	606
FAM120B	PDCD2	Q16342	594
FAM120B	ESR1	P03372	582
FAM120B	LTN1	O94822	575
FAM120B	XPR1	Q9UBH6	562
FAM120B	THRB	P10828	502
FAM120B	CDC34	P49427	488
FAM120B	ERMARD	Q5T6L9	479
FAM120B	WDR27	A2RRH5	477
FAM120B	RPL11	P25121	436

IntAct

38 interactions, top by confidence:

A	B	Type	Score
WDR20	USP12	psi-mi:“MI:0914”(association)	0.800
TRAF2	FAM120B	psi-mi:“MI:0915”(physical association)	0.670
FLCN	ZNF609	psi-mi:“MI:0914”(association)	0.530
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
DOK2	NCK2	psi-mi:“MI:0914”(association)	0.530
GSTM3	ECT2L	psi-mi:“MI:0914”(association)	0.530
LSP1	FAM120B	psi-mi:“MI:0915”(physical association)	0.400
RPL30	FAM120B	psi-mi:“MI:0915”(physical association)	0.370
	FAM120B	psi-mi:“MI:0915”(physical association)	0.370
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
HIF1AN	ARID1A	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
SPANXN4	UBA6	psi-mi:“MI:0914”(association)	0.350
NXF2B	MEIOC	psi-mi:“MI:0914”(association)	0.350
DNAJA2	DENND11	psi-mi:“MI:0914”(association)	0.350
FEM1A	RNF113A	psi-mi:“MI:0914”(association)	0.350
COP1	SPOP	psi-mi:“MI:0914”(association)	0.350
MTPN	PLCG1	psi-mi:“MI:0914”(association)	0.350
DONSON	HSP90AA5P	psi-mi:“MI:0914”(association)	0.350
PXDN	TRAF7	psi-mi:“MI:0914”(association)	0.350
SURF6	GTPBP10	psi-mi:“MI:0914”(association)	0.350
FAM133A	DNM1L	psi-mi:“MI:0914”(association)	0.350
FEM1A	LAD1	psi-mi:“MI:0914”(association)	0.350
EPB41L5	LIN7A	psi-mi:“MI:0914”(association)	0.350
ING2	TNRC18	psi-mi:“MI:0914”(association)	0.350
TNFAIP6	ITIH2	psi-mi:“MI:0914”(association)	0.350
TROAP	HARS2	psi-mi:“MI:0914”(association)	0.350
STN1	MTMR3	psi-mi:“MI:0914”(association)	0.350

BioGRID (54): FAM120B (Two-hybrid), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), SETX (Affinity Capture-Western), TRAF2 (Two-hybrid), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS), FAM120B (Affinity Capture-MS)

ESM2 similar proteins: A0A087WUL8, A0A0J9YX57, A0A1B0GV03, A2A6M5, A2A9R3, A5A3E0, A6NEF3, A6NI86, A8MZA4, B4DH59, B5DUH6, D3ZVV1, E9Q0N2, H0YKK7, H0YM25, O04492, O18737, P0C6Y7, P0CG38, P0CG39, P0DPF3, P0DX00, P0DX01, P0DX02, Q3BBV2, Q4R914, Q5TAG4, Q5TI25, Q5W0A0, Q6P3W6, Q6RI63, Q6S8J3, Q86T75, Q86X53, Q8HXZ7, Q8HXZ8, Q8HY00, Q8HY01, Q8HY03, Q8HY11

Diamond homologs: A6H7H1, Q5T035, Q6A0A9, Q6DEZ2, Q8C3F2, Q96EK7, Q9NX05, Q9NZB2, A6QNT4, Q6RI63

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

135 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	14
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2667 predictions. Top by Δscore:

Variant	Effect	Δscore
6:170323077:A:AG	acceptor_gain	1.0000
6:170323078:G:GG	acceptor_gain	1.0000
6:170323078:GGTT:G	acceptor_gain	1.0000
6:170323255:TCAAG:T	donor_loss	1.0000
6:170323258:AGGTG:A	donor_loss	1.0000
6:170323259:GGTGA:G	donor_loss	1.0000
6:170323260:GTG:G	donor_loss	1.0000
6:170323261:T:G	donor_loss	1.0000
6:170330444:TTCA:T	acceptor_loss	1.0000
6:170330446:CA:C	acceptor_loss	1.0000
6:170330447:A:AG	acceptor_gain	1.0000
6:170330447:AG:A	acceptor_loss	1.0000
6:170330448:G:GG	acceptor_gain	1.0000
6:170330448:GAT:G	acceptor_gain	1.0000
6:170323077:AG:A	acceptor_gain	0.9900
6:170323077:AGGTT:A	acceptor_gain	0.9900
6:170323078:GG:G	acceptor_gain	0.9900
6:170323078:GGTTG:G	acceptor_gain	0.9900
6:170330446:CAGA:C	acceptor_gain	0.9900
6:170348147:CTA:C	acceptor_loss	0.9900
6:170348148:TA:T	acceptor_loss	0.9900
6:170348149:A:AC	acceptor_loss	0.9900
6:170348150:G:GT	acceptor_loss	0.9900
6:170358220:TTTCA:T	acceptor_loss	0.9900
6:170358221:TTCA:T	acceptor_loss	0.9900
6:170358222:TCAG:T	acceptor_loss	0.9900
6:170358223:CAGG:C	acceptor_loss	0.9900
6:170358224:A:AC	acceptor_loss	0.9900
6:170358303:GCTT:G	donor_gain	0.9900
6:170358334:G:GG	donor_gain	0.9900

AlphaMissense

5985 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:170317562:T:A	W58R	0.998
6:170317562:T:C	W58R	0.998
6:170317580:T:A	W64R	0.998
6:170317580:T:C	W64R	0.998
6:170317518:T:A	V43D	0.997
6:170317691:T:A	W101R	0.997
6:170317691:T:C	W101R	0.997
6:170317701:G:C	R104P	0.997
6:170317521:A:T	D44V	0.995
6:170318073:T:C	L228P	0.995
6:170330481:T:A	W650R	0.995
6:170330481:T:C	W650R	0.995
6:170317394:G:C	G2R	0.994
6:170317415:T:C	F9L	0.994
6:170317417:T:A	F9L	0.994
6:170317417:T:G	F9L	0.994
6:170317564:G:C	W58C	0.994
6:170317564:G:T	W58C	0.994
6:170317781:T:C	F131L	0.994
6:170317783:C:A	F131L	0.994
6:170317783:C:G	F131L	0.994
6:170318067:C:A	A226D	0.994
6:170317407:T:C	L6S	0.993
6:170317416:T:C	F9S	0.993
6:170317520:G:C	D44H	0.993
6:170317544:T:A	W52R	0.993
6:170317544:T:C	W52R	0.993
6:170317693:G:C	W101C	0.993
6:170317693:G:T	W101C	0.993
6:170317824:T:C	L145P	0.993

dbSNP variants (sampled 300 via entrez): RS1000009209 (6:170346646 C>G), RS1000039432 (6:170306914 C>T), RS1000045266 (6:170346348 T>A,C), RS1000053028 (6:170296202 G>A), RS1000080221 (6:170296463 G>A), RS1000123893 (6:170321914 CTT>C), RS1000125569 (6:170362425 A>AAG), RS1000143042 (6:170376556 T>A), RS1000171458 (6:170397445 C>T), RS1000240374 (6:170340653 G>A,C), RS1000250855 (6:170400629 A>C,G), RS1000263426 (6:170331019 A>G), RS1000271439 (6:170382809 A>G), RS1000297169 (6:170362247 C>T), RS1000320982 (6:170319348 G>A,T)

Disease associations

OMIM: gene MIM:612266 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), primary amenorrhea (MONDO:1060208)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001255_3	Type 1 diabetes	8.000000e-09
GCST005588_31	Idiopathic dilated cardiomyopathy	7.000000e-06
GCST006065_19	Glaucoma (primary open-angle)	9.000000e-09
GCST007325_94	General risk tolerance (MTAG)	1.000000e-10
GCST009191_3	Paracentral lobule volume	6.000000e-06
GCST011494_36	Daytime nap	9.000000e-12

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009094	idiopathic dilated cardiomyopathy
EFO:0008579	risk-taking behaviour
EFO:0007828	daytime rest measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases methylation	3
sodium arsenite	decreases expression, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
bisphenol F	affects cotreatment, decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	increases expression	1
beta-methylcholine	affects expression	1
ICG 001	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Decitabine	affects expression	1
Acetaminophen	increases expression	1
Cisplatin	affects expression	1
Curcumin	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Indomethacin	affects cotreatment, decreases expression	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
1-Methyl-3-isobutylxanthine	decreases expression, affects cotreatment	1
Aflatoxin B1	decreases methylation	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

76 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists